John Theurer Cancer Center Enrolls First Patients for Groundbreaking Phase II Clinical Trial for Glioblastoma

07:00 EDT 3 Oct 2018 | Pharmaceutical Processing

News
Glioblastoma is the most common and aggressive form of primary brain cancer, with limited available FDA-approved treatments and a median survival of only 15 months from diagnosis.
Contributed Author: 
John Theurer Cancer Center
Topics: 
Oncology

More From BioPortfolio on "John Theurer Cancer Center Enrolls First Patients for Groundbreaking Phase II Clinical Trial for Glioblastoma"